Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VATHOS: 24‑week study of budesonide–formoterol MDI in inadequately controlled asthma
jRCT2031210576Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
01
Overview
Randomised, double-blind trial of budesonide and formoterol in asthma (4 arms), sponsored by AstraZeneca. Primary endpoints: Change from baseline in morning pre-dose trough FEV1 over Weeks 12 to 24 and Change from baseline in morning pre-dose trough FEV1 over Weeks 12 to 24 (duplicate listing). Started Feb 2022; status: completed.
02
Drugs
budesonideformoterol
03
Conditions
asthma
Beyond the preview
Go deeper on jRCT2031210576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210576.